1	Modification	_	NN	_	_	10	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	cysteine	_	NN	_	_	2	PMOD	_	_
4	179	_	CD	_	_	3	NMOD	_	_
5	of	_	IN	_	_	3	NMOD	_	_
6	IkappaBalpha	_	NN	_	_	7	NMOD	_	_
7	kinase	_	NN	_	_	5	PMOD	_	_
8	by	_	IN	_	_	1	NMOD	_	_
9	nimbolide	_	NN	_	_	8	PMOD	_	_
10	leads	_	VBZ	_	_	0	ROOT	_	_
11	to	_	TO	_	_	10	VMOD	_	_
12	down-regulation	_	NN	_	_	11	PMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	NF-kappaB-regulated	_	JJ	_	_	16	NMOD	_	_
15	cell	_	NN	_	_	16	NMOD	_	_
16	survival	_	NN	_	_	13	PMOD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	proliferative	_	JJ	_	_	19	NMOD	_	_
19	proteins	_	NNS	_	_	17	CONJ	_	_
20	and	_	CC	_	_	12	COORD	_	_
21	sensitization	_	NN	_	_	20	CONJ	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	tumor	_	NN	_	_	24	NMOD	_	_
24	cells	_	NNS	_	_	22	PMOD	_	_
25	to	_	TO	_	_	21	NMOD	_	_
26	chemotherapeutic	_	JJ	_	_	27	NMOD	_	_
27	agents	_	NNS	_	_	25	PMOD	_	_
28	.	_	.	_	_	10	P	_	_
		
1	Reverse	_	JJ	_	_	2	NMOD	_	_
2	pharmacology	_	NN	_	_	25	VMOD	_	_
3	,	_	,	_	_	2	P	_	_
4	also	_	RB	_	_	5	VMOD	_	_
5	called	_	VBN	_	_	2	APPO	_	_
6	the	_	DT	_	_	12	NMOD	_	_
7	"	_	``	_	_	12	P	_	_
8	bedside	_	JJ	_	_	12	NMOD	_	_
9	to	_	TO	_	_	8	AMOD	_	_
10	bench	_	NN	_	_	9	PMOD	_	_
11	"	_	``	_	_	12	P	_	_
12	approach	_	NN	_	_	5	VMOD	_	_
13	,	_	,	_	_	12	P	_	_
14	that	_	WDT	_	_	15	VMOD	_	_
15	deals	_	VBP	_	_	12	NMOD	_	_
16	with	_	IN	_	_	15	VMOD	_	_
17	new	_	JJ	_	_	16	PMOD	_	_
18	uses	_	VBZ	_	_	17	NMOD	_	_
19	for	_	IN	_	_	15	VMOD	_	_
20	a	_	DT	_	_	24	NMOD	_	_
21	well	_	RB	_	_	22	AMOD	_	_
22	known	_	JJ	_	_	24	NMOD	_	_
23	molecular	_	JJ	_	_	24	NMOD	_	_
24	entity	_	NN	_	_	19	PMOD	_	_
25	has	_	VBZ	_	_	0	ROOT	_	_
26	been	_	VBN	_	_	25	VC	_	_
27	used	_	VBN	_	_	26	VC	_	_
28	extensively	_	RB	_	_	27	VMOD	_	_
29	in	_	IN	_	_	27	VMOD	_	_
30	cancer	_	NN	_	_	32	NMOD	_	_
31	drug	_	NN	_	_	32	NMOD	_	_
32	development	_	NN	_	_	29	PMOD	_	_
33	to	_	TO	_	_	27	VMOD	_	_
34	identify	_	VB	_	_	33	IM	_	_
35	novel	_	JJ	_	_	36	NMOD	_	_
36	compounds	_	NNS	_	_	34	VMOD	_	_
37	and	_	CC	_	_	34	COORD	_	_
38	delineate	_	VB	_	_	37	CONJ	_	_
39	their	_	PRP$	_	_	40	NMOD	_	_
40	mechanisms	_	NNS	_	_	38	VMOD	_	_
41	of	_	IN	_	_	40	NMOD	_	_
42	action	_	NN	_	_	41	PMOD	_	_
43	.	_	.	_	_	25	P	_	_
		
1	Here	_	RB	_	_	4	VMOD	_	_
2	,	_	,	_	_	4	P	_	_
3	we	_	PRP	_	_	4	VMOD	_	_
4	show	_	VBP	_	_	0	ROOT	_	_
5	that	_	IN	_	_	4	VMOD	_	_
6	nimbolide	_	NN	_	_	15	VMOD	_	_
7	,	_	,	_	_	6	P	_	_
8	a	_	DT	_	_	9	NMOD	_	_
9	triterpenoid	_	JJ	_	_	6	APPO	_	_
10	isolated	_	VBN	_	_	9	APPO	_	_
11	from	_	IN	_	_	10	VMOD	_	_
12	Azadirachta	_	NN	_	_	13	NMOD	_	_
13	indica	_	NN	_	_	11	PMOD	_	_
14	,	_	,	_	_	6	P	_	_
15	enhanced	_	VBD	_	_	5	SUB	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	apoptosis	_	NN	_	_	15	VMOD	_	_
18	induced	_	VBN	_	_	17	APPO	_	_
19	by	_	IN	_	_	18	VMOD	_	_
20	inflammatory	_	JJ	_	_	21	NMOD	_	_
21	cytokines	_	NNS	_	_	19	PMOD	_	_
22	and	_	CC	_	_	21	COORD	_	_
23	chemotherapeutic	_	JJ	_	_	24	NMOD	_	_
24	agents	_	NNS	_	_	22	CONJ	_	_
25	in	_	IN	_	_	15	VMOD	_	_
26	tumor	_	NN	_	_	27	NMOD	_	_
27	cells	_	NNS	_	_	25	PMOD	_	_
28	.	_	.	_	_	4	P	_	_
		
1	This	_	DT	_	_	2	NMOD	_	_
2	limonoid	_	NN	_	_	3	VMOD	_	_
3	abrogated	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	expression	_	NN	_	_	3	VMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	proteins	_	NNS	_	_	6	PMOD	_	_
8	associated	_	VBN	_	_	7	APPO	_	_
9	with	_	IN	_	_	8	VMOD	_	_
10	cell	_	NN	_	_	11	NMOD	_	_
11	survival	_	NN	_	_	9	PMOD	_	_
12	(	_	(	_	_	13	P	_	_
13	Bcl-2	_	NN	_	_	11	PRN	_	_
14	,	_	,	_	_	13	P	_	_
15	Bcl-xL	_	NN	_	_	13	COORD	_	_
16	,	_	,	_	_	15	P	_	_
17	IAP-1	_	NN	_	_	15	COORD	_	_
18	,	_	,	_	_	17	P	_	_
19	and	_	CC	_	_	17	COORD	_	_
20	IAP-2	_	NN	_	_	19	CONJ	_	_
21	)	_	)	_	_	13	P	_	_
22	,	_	,	_	_	11	P	_	_
23	proliferation	_	NN	_	_	11	COORD	_	_
24	(	_	(	_	_	26	P	_	_
25	cyclin	_	NN	_	_	26	NMOD	_	_
26	D1	_	NN	_	_	23	PRN	_	_
27	)	_	)	_	_	26	P	_	_
28	,	_	,	_	_	23	P	_	_
29	invasion	_	NN	_	_	23	COORD	_	_
30	(	_	(	_	_	31	P	_	_
31	MMP-9	_	NN	_	_	29	PRN	_	_
32	)	_	)	_	_	31	P	_	_
33	,	_	,	_	_	29	P	_	_
34	and	_	CC	_	_	29	COORD	_	_
35	angiogenesis	_	NN	_	_	34	CONJ	_	_
36	(	_	(	_	_	37	P	_	_
37	VEGF	_	NN	_	_	35	PRN	_	_
38	)	_	)	_	_	37	P	_	_
39	,	_	,	_	_	7	P	_	_
40	all	_	DT	_	_	7	APPO	_	_
41	regulated	_	VBN	_	_	40	APPO	_	_
42	by	_	IN	_	_	41	VMOD	_	_
43	nuclear	_	JJ	_	_	48	NMOD	_	_
44	factor	_	NN	_	_	48	NMOD	_	_
45	(	_	(	_	_	48	P	_	_
46	NF	_	NN	_	_	48	NMOD	_	_
47	)	_	)	_	_	48	P	_	_
48	-kappaB	_	NN	_	_	42	PMOD	_	_
49	.	_	.	_	_	3	P	_	_
		
1	Nimbolide	_	NN	_	_	2	VMOD	_	_
2	inhibited	_	VBD	_	_	0	ROOT	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	activation	_	NN	_	_	2	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	NF-kappaB	_	NN	_	_	5	PMOD	_	_
7	induced	_	VBN	_	_	4	APPO	_	_
8	by	_	IN	_	_	7	VMOD	_	_
9	carcinogens	_	NNS	_	_	8	PMOD	_	_
10	and	_	CC	_	_	9	COORD	_	_
11	inflammatory	_	JJ	_	_	12	NMOD	_	_
12	stimuli	_	NNS	_	_	10	CONJ	_	_
13	.	_	.	_	_	2	P	_	_
		
1	Constitutively	_	RB	_	_	2	AMOD	_	_
2	active	_	JJ	_	_	3	NMOD	_	_
3	NF-kappaB	_	NN	_	_	9	VMOD	_	_
4	found	_	VBN	_	_	3	APPO	_	_
5	in	_	IN	_	_	4	VMOD	_	_
6	most	_	JJS	_	_	8	NMOD	_	_
7	tumor	_	NN	_	_	8	NMOD	_	_
8	cells	_	NNS	_	_	5	PMOD	_	_
9	was	_	VBD	_	_	0	ROOT	_	_
10	also	_	RB	_	_	9	VMOD	_	_
11	inhibited	_	VBN	_	_	9	VC	_	_
12	.	_	.	_	_	9	P	_	_
		
1	We	_	PRP	_	_	2	VMOD	_	_
2	found	_	VBD	_	_	0	ROOT	_	_
3	that	_	IN	_	_	2	VMOD	_	_
4	suppression	_	NN	_	_	10	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	NF-kappaB	_	NN	_	_	7	NMOD	_	_
7	activation	_	NN	_	_	5	PMOD	_	_
8	by	_	IN	_	_	4	NMOD	_	_
9	nimbolide	_	NN	_	_	8	PMOD	_	_
10	was	_	VBD	_	_	3	SUB	_	_
11	caused	_	VBN	_	_	10	VC	_	_
12	by	_	IN	_	_	11	VMOD	_	_
13	inhibition	_	NN	_	_	12	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	IkappaB	_	NN	_	_	16	NMOD	_	_
16	kinase	_	NN	_	_	14	PMOD	_	_
17	(	_	(	_	_	18	P	_	_
18	IKK	_	NN	_	_	16	PRN	_	_
19	)	_	)	_	_	18	P	_	_
20	,	_	,	_	_	13	P	_	_
21	which	_	WDT	_	_	22	VMOD	_	_
22	led	_	VBD	_	_	13	NMOD	_	_
23	to	_	TO	_	_	22	VMOD	_	_
24	suppression	_	NN	_	_	23	PMOD	_	_
25	of	_	IN	_	_	24	NMOD	_	_
26	IkappaBalpha	_	NN	_	_	27	NMOD	_	_
27	phosphorylation	_	NN	_	_	25	PMOD	_	_
28	and	_	CC	_	_	27	COORD	_	_
29	degradation	_	NN	_	_	28	CONJ	_	_
30	,	_	,	_	_	29	P	_	_
31	nuclear	_	JJ	_	_	32	NMOD	_	_
32	translocation	_	NN	_	_	29	COORD	_	_
33	,	_	,	_	_	32	P	_	_
34	DNA	_	NN	_	_	35	NMOD	_	_
35	binding	_	NN	_	_	32	COORD	_	_
36	,	_	,	_	_	35	P	_	_
37	and	_	CC	_	_	35	COORD	_	_
38	gene	_	NN	_	_	39	NMOD	_	_
39	transcription	_	NN	_	_	37	CONJ	_	_
40	.	_	.	_	_	2	P	_	_
		
1	Reducing	_	NN	_	_	2	NMOD	_	_
2	agent	_	NN	_	_	3	VMOD	_	_
3	reversed	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	action	_	NN	_	_	3	VMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	limonoid	_	NN	_	_	6	PMOD	_	_
9	,	_	,	_	_	3	P	_	_
10	suggesting	_	VBG	_	_	3	VMOD	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	involvement	_	NN	_	_	10	VMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	a	_	DT	_	_	16	NMOD	_	_
15	cysteine	_	JJ	_	_	16	NMOD	_	_
16	residue	_	NN	_	_	13	PMOD	_	_
17	.	_	.	_	_	3	P	_	_
		
1	Replacement	_	NN	_	_	8	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	Cys(179)	_	NN	_	_	2	PMOD	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	IKK-beta	_	NN	_	_	4	PMOD	_	_
6	with	_	IN	_	_	1	NMOD	_	_
7	alanine	_	NN	_	_	6	PMOD	_	_
8	abolished	_	VBD	_	_	0	ROOT	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	effect	_	NN	_	_	8	VMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	nimbolide	_	NN	_	_	11	PMOD	_	_
13	,	_	,	_	_	8	P	_	_
14	suggesting	_	VBG	_	_	8	VMOD	_	_
15	that	_	IN	_	_	14	VMOD	_	_
16	Cys(179)	_	NN	_	_	17	VMOD	_	_
17	plays	_	VBZ	_	_	15	SUB	_	_
18	a	_	DT	_	_	20	NMOD	_	_
19	critical	_	JJ	_	_	20	NMOD	_	_
20	role	_	NN	_	_	17	VMOD	_	_
21	in	_	IN	_	_	17	VMOD	_	_
22	inhibiting	_	VBG	_	_	21	PMOD	_	_
23	the	_	DT	_	_	25	NMOD	_	_
24	NF-kappaB	_	NN	_	_	25	NMOD	_	_
25	activation	_	NN	_	_	22	VMOD	_	_
26	.	_	.	_	_	8	P	_	_
		
1	Overall	_	RB	_	_	5	VMOD	_	_
2	,	_	,	_	_	5	P	_	_
3	our	_	PRP$	_	_	4	NMOD	_	_
4	results	_	NNS	_	_	5	VMOD	_	_
5	indicate	_	VBP	_	_	0	ROOT	_	_
6	that	_	IN	_	_	5	VMOD	_	_
7	nimbolide	_	NN	_	_	8	VMOD	_	_
8	can	_	MD	_	_	6	SUB	_	_
9	sensitize	_	VB	_	_	8	VC	_	_
10	tumor	_	NN	_	_	11	NMOD	_	_
11	cells	_	NNS	_	_	9	VMOD	_	_
12	to	_	TO	_	_	9	VMOD	_	_
13	chemotherapeutic	_	JJ	_	_	14	NMOD	_	_
14	agents	_	NNS	_	_	12	PMOD	_	_
15	through	_	IN	_	_	9	VMOD	_	_
16	interaction	_	NN	_	_	15	PMOD	_	_
17	with	_	IN	_	_	16	NMOD	_	_
18	IKK	_	NN	_	_	17	PMOD	_	_
19	,	_	,	_	_	9	P	_	_
20	leading	_	VBG	_	_	9	VMOD	_	_
21	to	_	TO	_	_	20	VMOD	_	_
22	inhibition	_	NN	_	_	21	PMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	NF-kappaB-regulated	_	JJ	_	_	25	NMOD	_	_
25	proteins	_	NNS	_	_	23	PMOD	_	_
26	.	_	.	_	_	5	P	_	_
		
